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BACKGROUND Management of small coronary vessel disease with
percutaneous coronary interventions is often associated with high
recurrences and an increased risk of late or very late adverse events,
including stent thrombosis. Currently, little is known about bio-
vascular scaffold (BVS) behavior in this setting.
METHODS A retrospective cohort analysis was performed in consec-
utive patients treated with BVS implantation in vessels whose diam-
eter was <2.8mm at 3 high volume Italian centers with a certiﬁcated
experience of >2.5 years of BVS implantation. Primary end-point was
the occurrence of BVS failure (a composite of target lesion revascu-
larization, TLR, and BVS deﬁnite thrombosis) at the longest available
follow up.
RESULTS A total of 121 patients (133 lesions) were treated between
March 2013-December 2014. Baseline clinical and angiographic char-
acteristics, that describe a highly complex patient population, are
described in Table. Procedural success was obtained in all patients. In-
hospital events included 2 perforations (1.5%) both sealed with
covered stents. At the longest available clinical follow up (average
126 months), 70% of patients were still on dual antiplatelet treat-
ment. Angiographic follow-up was performed in 10% of patients.
Eleven patients (8.2%) suffered a BVS failure, including 11 (8.2%) TLR
and 2 (1.6%) scaffold thrombosis. We also registered 2 (1.6%) deaths
(one cardiac) and 2 (1.6%) target-vessel myocardial infarctions.
Table. Clinical, Angiographic and Procedural characteristics.Patients, n 121Lesions treated, n 133 In-stent restenosis, % 19.4Age, years 61.78.8 Thrombus-containing
lesions, %17.9Males, % 82.3 Average vessel
diameter, mmSD
2.470.14Diabetes Mellitus, % 30.6 Percent diameter
stenosis, %SD
79.511.8Hypertension, % 70.0 Predilatation, % 96.3History of smoke, % 28.4 Predilatation balloon
diameter, mmSD
2.50.34LVEF, %SD 53.27.2 Biovascular scaffold
diameter, mmSD2.630.23Clinical Presentation Biovascular scaffold
length(s), mmSD
32.914.2Stable coronary
artery disease,
%66.2 Biovascular scaffold
underexpansion, %3.8NSTEMI, % 22.0 Postdilatation, % 94.8STEMI, % 21.8 Postdilatation balloon
size, mmSD
2.80.19Type B2/C lesions, % 70.7 Intravascular imaging
guidance, %11.1CONCLUSIONS To the best of our knowledge, this is the largest reg-
istry of small coronary vessels treated with BVS. In this cohort of
consecutive patients, BVS implantation was technically feasible and
effective in maintaining vessel patency after 12 months.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
KEYWORDS Bioabsorbable scaffolds, Small Vessel DiseaseTCT-517
Long term clinical outcome following Bioresorbable Vascular Scaffold
Implantation for the Treatment of Coronary In-stent Restenosis: a
Multicenter Italian Experience
Elisabetta Moscarella,1 Attilio Varricchio,2 Francesco Granata,2
Sebastian Coscarelli,3 Eugenio Stabile,4 Azeem Latib,5 Alfonso Ielasi,6
Bernardo Cortese,7 Maurizio Tespili,6 Paolo Calabrò,1 Akihito Tanaka,5
Claudia Capozzolo,8 Antonio Colombo5
1Department of Cardiothoracic Science, Second University of Naples,
Naples, Italy; 2Santa Maria della Pietà Hospital, Nola, Italy;
3Interventional Cardiology, San Martino Hospital, Belluno, Italy;
4Università degli studi di Napoli Federico II, Naples, Italy; 5Ospedale
San Raffaele, Milan, Italy; 6Azienda Ospedaliera Bolognini, Seriate (BG),
Italy; 7A.O. Fatebenefratelli Milano, Milano, Italy; 8AORN dei Colli - PO
Monaldi, Naples, Italy
BACKGROUND Treatment of in-stent restenosis (ISR) is still chal-
lenging for interventional cardiologists. In this contest the use of
bioresorbable vascular scaffold (BVS) appears very attractive as it al-
lows drug delivery combined with transient vessel scaffolding thus
obviating the limitations of drug-eluting stent or balloon as ISR
therapy. Aim of this multicenter registry was to investigate the
feasibility of BVS use in ISR lesions.
METHODS A prospective analysis was performed on all patients that
underwent percutaneous coronary intervention (PCI) with BVS im-
plantation for ISR at 7 Italian Centers. Primary endpoints were pro-
cedural success deﬁned as the successful delivery and deployment of
the BVS at the target lesion with less than 30% ﬁnal residual stenosis
without in-hospital major adverse cardiac and/or cerebro-vascular
events (MACCE) deﬁned as a composite of cardiac death, Q-wave
myocardial infarction, stroke, or any repeat target lesion revasculari-
zation (surgical or percutaneous).
RESULTS From April 2012 to June 2014, a total of 113 patients (124
lesions) underwent PCI for ISR with BVS implantation at the partici-
pating Centers. Among the ISR lesions, the majority were DES-ISR (74,
59.7%); 35 (28.2%) recurrent-ISR and according to the angiographic
pattern 79 (63.7%) were deﬁned as diffuse-ISR. The mean patient age
was 65.910 years and 105 patients (84.7%) were male. Type 2 dia-
betes mellitus was present in 35 (28%) patients while chronic kidney
disease in 19 (15.3%). PCI procedures were performed in 71 (57.3%)
patients presenting with stable CAD, 46 (37.1%) with UA/NSTEMI and
7 (5.6%) with STEMI. Intracoronary imaging evaluation was performed
in 26 (21%) lesions before and in 30 (24.2%) lesions post-BVS im-
plantation. Target lesion length was 28.0615 mm requiring the use of
1.40.6 BVS per lesion, with a mean BVS length of 34.818.4 mm per
lesion. Lesion pre dilatation was mandatory, and post dilatation was
needed in 87.9% of cases. Procedural success was achieved in 123
(99.2%) patients. In one patient a bailout DES implantation was
needed because of proximal BVS edge dissection occurrence not
suitable for a second BVS implantation. No in-hospital and 30-day
MACCE occurred. At median follow-up time of 17 months (IQR 12-23)
MACCE rate was 12.1%. TLR per patient was 7.1%, TLR per lesion 6.5%,
while cardiac death 2.4%. Deﬁnite BVS-in-stent thrombosis was re-
ported in 1 patient (0.8%).
CONCLUSIONS To the best of our knowledge, we report the largest
registry of complex ISR lesions treated with BVS. The results of our
registry suggest that BVS implantation for the treatment of ISR is
technically feasible and associated with favorable mid-term clinical
outcomes. These data could be considered hypothesis generating for a
future randomized clinical trial.
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BACKGROUND Everolimus eluting ABSORB(tm) bioresorbable
vascular scaffold (BVS) represents a novel approach for PCI with
transient vessel support and drug delivery without the long term
limitations of metallic DES. Diabetic patients tend to have a worse
B212 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5prognosis regardless of the therapeutic strategy used. The aim of this
subgroup analysis was to evaluate the clinical outcomes of diabetic
patients treated with BVS as compared to non-diabetic subjects.
METHODS A single center all-comers absorb registry was performed
from oct 2012 to feb 2015. A total of 150 consecutive patients with 182
lesions (246 BVS) were included prospectively. 25 diabetics patients
received BVS for 37 lesions, and 125 non-diabetics patients received
BVS for 145 lesions.
RESULTS The basal characteristics of our population was a male/fe-
male ratio of 115/35, with mean age of 559 years. 15% had a family
history of ischemic heart disease, 73% smoking (27% former smokers),
49% hypertension, 51% Dyslipidemia, 4% had prior ischemic heart
disease and 3% prior PCI. 90% of patients had preserved EF. The
clinical presentation was ACS in 94,6% with MI in 76.5%(n¼115) of
patients(42% NSTEMI, 35 STEMI). 26% had multi-vessel disease. The
most frequently affected artery was the left anterior descending (47%
LAD; 15% Circ; 31% RCA; 2.2% LM). Most of the lesions were B2(59%).
Only a 1.1% were CTO. Pre-dilating and post-dilating lesions were
done in the 59/60%. Intracoronary imaging techniques were per-
formed in 89 patients(49%), 91% were OCT. Regarding the whole
group, during a mean follow-up of 294226 days there were 4.7% of
MACE due to TLR, but with no deaths. There were no big differences
in baseline characteristics between diabetics and non diabetics apart
from diabetic patients were less smokers (64% vs 87%; p¼0.01) and
more hypertensive (72% vs 44%;p¼0.01), dyslipidemic (80% vs
45%;p¼0.001), and more of them had previous history of ischemic
heart disease, previous revascularization (16% vs 1% & 14% vs 0%;
p<0.001) and more use of new antiplatelet agents (68% vs
50%;p¼0,03). They had higher rates of pre-dilation (81% vs 54%;
p¼0.005) probably due to more complex lesions (type B2 and C¼ 59%
vs 34%; p¼0.008) and more calciﬁed lesions (16% vs 6%; p¼0.048).
The number of scaffolds per lesion was higher (>2 BVS in 43% vs 21%;
p¼0.018). Regarding the diabetics subgroup, during a mean follow-up
of 294226 they showed a non signiﬁcant but striking trend toward
more MACE (10.8% vs 3.4%; p¼0.056) and restenosis was higher in the
diabetic subgroup (8% vs 0%; p¼0.005). There were no statistical
differences in stent thrombosis (8% vs 3.4%; p¼0.30) although the
difference is remarkable.
CONCLUSIONS In the present analysis, diabetic patients treated with
BVS trended to have more complex lesions with increased need for
pre-dilatation and implantation of more than one BVS. They showed a
statistically non-signiﬁcant trend toward more MACE, although they
had more use of new antiplatelet agents. Intrastent restenosis was
higher in diabetics.
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
TCT-519
Feasibility and performance of everolimus-eluting bioresorbable vascular
scaffolds (BVS) in long lesions (>25 mm): all-comers absorb registry with
mid-term follow-up
Santiago J. Camacho Freire,1 Jessica Roa-Garrido,1 Rosa M. Cardenal,1
Antonio Gomez Menchero,1 Javier Leon Jimenez,1
Francisco J. Landero Garcia,1 Prudencia Gomez Fernandez,1
Jose F. Diaz Fernandez1
1Complejo Hospitalario Juan Ramón Jiménez, Huelva, Spain
BACKGROUND Everolimus eluting ABSORB(tm) bioresorbable
vascular scaffold (BVS) represents a novel approach for PCI with
transient vessel support and drug delivery without the long term
limitations of metallic DES. However, the current use of BVS is still
restricted to non-complex lesions. The aim of this subgroup analysis
was to evaluate the feasibility and performance of BVS in long lesions
(>25 mm).
METHODS A single center all-comers absorb registry was performed
from oct 2012 to feb 2015. A total of 150 consecutive patients with 182
lesions (246 BVS) were included, of whom 36.3% had long lesions (66
lesions), and 63.7% had non-long lesions (116 lesions).
RESULTS The male/female ratio was 115/35, with a mean age of 559
years. 15% had a family history of ischemic heart disease, 73%
smoking (27% former smokers), 49% hypertension, 51% Dyslipidemia,
4% had prior ischemic heart disease and 3% prior PCI. 90% of patients
had preserved EF. The clinical presentation was ACS in 94,6% with MI
in 76.5%(n¼115) of patients(42% NSTEMI, 35 STEMI). 26% had multi-
vessel disease. The most frequently affected artery was the left
anterior descending (47% LAD; 15% Circ; 31% RCA; 2.2% LM). Most of
the lesions were B2 (59%), 36% long lesions (>25 mm). There were
more long lesions in RCA and Marginal branches (p¼0.04). Only a 1.1%
were CTO. Pre-dilatation and post-dilatation was done in the 59/60%.Intracoronary imaging techniques were performed in 89 patients
(49%), 91% were OCT. Regarding the whole group, during a median
follow-up of 294226 days there were 4.7% of MACE due to TLR, but
with no deaths. There were 6 stent thrombosis, in 2 of them was due
to non-adherence. All of them resolved with ACTP balloon or with a
new BVS implant. Regarding the subgroup of patients with long le-
sions compared to non-long lesions patients, there were no differ-
ences in ostium affectation (12% vs 8%;p¼0,44), bifurcation lesion
was present in 24% vs 14%(p¼0,1). Pre-dilatation was more
frequent(70% vs 50%;p¼0,01) and post-dilation also(70% vs
61%;p¼0,25), probably due to more complex lesions (type B2 and C¼
68% vs 32%; p<0.0001) and more calciﬁed lesions (14% vs
5%;p¼0,046). All CTOs were long lesions (p¼0.04). There was higher
number of scaffolds per lesion (>2 BVS in 54% vs 9%;p<0,0001) and
obviously, more overlapping (44.2 vs 8.8%; p<0.001) and there were
differences in the mean length of BVS in mm(40.7 vs
18.2 mm;p<0.001). They presented a higher rate of complications
during the implantation (consist of distal edge dissection with TIMI 3
ﬂow: 13.4 vs 5.8%; p¼0.003). During a mean follow-up of 294226
days there was no differences in MACE between groups (TLR 4.5% vs
3.4%; p¼0.71).
CONCLUSIONS In the present analysis, patients treated with BVS in
long lesions showed more complex lesions with increased procedural
complexity, including acute complications, although they showed a
statistically non-difference MACE and stent thrombosis. Further
studies are needed to conﬁrm these ﬁndings.
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BACKGROUND Bioresorbable vascular scaffolds (BVS) implantation in
selected patients with stable angina has been demonstrated feasible
and safe. However data concerning BVS implantation in the setting of
primary percutaneous coronary intervention (P-PCI) for ST-elevation
myocardial infarction (STEMI) is scarce. Therefore, we report our one-
year experience of STEMI patients treated with BVS.
METHODS From April 1st 2013 to March 30th 2014, BVS (Absorb TM,
Abbott Vascular, Santa Clara, CA, USA) became available at our insti-
tution. Selection of lesions to be treated with BVS was left to the
discretion of the interventional cardiologist. For all patients, clinical,
procedural characteristics and in-hospital outcomes were systemati-
cally and prospectively collected in our interventional database. Over
the study period, 343 patients were treated with P-PCI for STEMI; BVS
were implanted in 56 patients (16%), DES in 166 (48%) and BMS in 121
(35%). Baseline demographics and clinical characteristics of patients
were comparable in BVS and DES groups, allowing comparison of
these two groups.
RESULTS Optimal angiographic result was achieved in 88% of cases in
both groups (100% of angiographic procedural success in both
groups). In-hospital MACE rates (death, myocardial infarction, urgent
PCI) were 0% and 1% in BVS and DES groups, respectively. Acute stent
thrombosis (ST) occurred in one patient treated with DES and in none
of the BVS patients. Per-procedural complications rates (dissection,
no-reﬂow phenomenon, side-branch closure, arrhythmia or emboli-
zation) were 7% in both groups. Prasugrel or ticagrelor were used as
the second dual anti-platelet drug in addition to aspirin in 88% of BVS
cases and in 70% of DES cases (p<0,05). One-year outcome will be
presented.
CONCLUSIONS In our non-randomized series of P-PCI for STEMI,
procedural and in-hospital outcomes of patients treated with BVS
were similar as compared with patients treated with conventional
DES. Use of newer anti-platelet drugs (i.e. ticagrelor or prasugrel) was
more frequent among patients treated with BVS as compared to DES.
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